Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29710695 | 1.00 | EPHX2 (0.44) | EPHX2KMT2AMAPTMAPK1CYP2C19 | |
| SCHEMBL223632 | 1.00 | EPHX2 (0.44) | EPHX2KMT2AMAPTMAPK1CYP2C19 | |
| SCHEMBL31180745 | 1.00 | EPHX2 (0.44) | EPHX2KMT2AMAPTMAPK1CYP2C19 | |
| SCHEMBL16678151 | 1.00 | EPHX2 (0.44) | EPHX2KMT2AMAPTMAPK1CYP2C19 | |
| Hydrochloric Acid SCHEMBL1461313 | 0.98 | EPHX2 (0.43) | EPHX2KMT2AMAPTMAPK1CYP2C19 | |
| SCHEMBL6230510 | 0.88 | KMT2A (0.38) | EPHX2KMT2AMAPTMAPK1CYP2C19 | |
| SCHEMBL8417567 | 0.86 | EPHX2 (0.39) | EPHX2ALDH1A1LMNA | |
| SCHEMBL11295865 | 0.85 | EPHX2 (0.42) | EPHX2KMT2AMAPTMAPK1CYP2C19 | |
| SCHEMBL18230678 | 0.85 | EPHX2 (0.42) | EPHX2KMT2AMAPTMAPK1CYP2C19 | |
| SCHEMBL7080802 | 0.84 | EPHX2 (0.44) | EPHX2KMT2AMAPTMAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12551465-B2 | Pharmaceutical composition for treatment of hypertrophic cardiomyopathy and treatment method using same composition | CELLTRION INC. (KR) | 2026-02-17 | — | — | US | claimed |
| US-20250320198-A1 | SALT OF ENDOTHELIN A (ETA) RECEPTOR ANTAGONIST COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD (CN) | 2025-10-16 | — | — | US | claimed |
| EP-4606802-A1 | SALT AND CRYSTAL FORM OF HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shanghai Hansoh Biomedical Co., Ltd. (CN) | 2025-08-27 | — | — | EP | claimed |
| EP-4545520-A1 | SALT OF ENDOTHELIN A (ETA) RECEPTOR ANTAGONIST COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | Shenzhen Salubris Pharmaceuticals Co., Ltd (CN) | 2025-04-30 | — | — | EP | claimed |
| US-20230190708-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY AND TREATMENT METHOD USING SAME COMPOSITION | CELLTRION, INC. (KR) | 2023-06-22 | — | — | US | claimed |
| EP-4140482-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY AND TREATMENT METHOD USING SAME COMPOSITION | Celltrion, Inc. (KR) | 2023-03-01 | — | — | EP | claimed |
| EP-0863872-B1 | PREPARATION OF CHIRAL 3-HYDROXY-2-PYRROLIDINONE DERIVATIVES | SYNGENTA LTD (GB) | 2002-05-29 | — | — | EP | claimed |
| EP-0739874-B1 | Preparation of polyalkylated cyclopentadienes from isobornyl carboxylates | ALBEMARLE CORP (US) | 1999-09-22 | — | — | EP | claimed |
| EP-0863872-A1 | PREPARATION OF CHIRAL 3-HYDROXY-2-PYRROLIDINONE DERIVATIVES | ZENECA LIMITED (GB) | 1998-09-16 | — | — | EP | claimed |
| US-5710283-A | Preparation of chiral pyrrolidinone derivatives | ZENECA LIMITED (GB) | 1998-01-20 | — | — | US | claimed |
| US-5648578-A | Preparation of polyalkylated cyclopentadienes from isobornyl carboxylates | ALBEMARLE CORPORATION (US) | 1997-07-15 | — | — | US | claimed |
| WO-1997019920-A1 | PREPARATION OF CHIRAL 3-HYDROXY-2-PYRROLIDINONE DERIVATIVES | ZENECA LIMITED (GB) | 1997-06-05 | — | — | WO | claimed |
| EP-0739874-A1 | Preparation of polyalkylated cyclopentadienes from isobornyl carboxylates | ALBEMARLE CORPORATION (US) | 1996-10-30 | — | — | EP | claimed |
| JP-8310975-A | — | — | None | — | — | JP | disclosed |
| JP-8310975-A | — | — | None | — | — | JP | disclosed |
| EP-4238966-B1 | TETRAHYDRONAPHTHALENE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | GUANGZHOU HENOVCOM BIOSCIENCE CO LTD (CN) | 2026-03-11 | — | — | EP | disclosed |
| US-4389525-A | Process for the resolution of some interphenylene 9-thia-11-oxo-12-azaprostanoic acids | MERCK & CO., INC. (US) | 1983-06-21 | — | — | US | disclosed |
| US-4379792-A | Anti-inflammatory composition | MERCK & CO., INC. (US) | 1983-04-12 | — | — | US | disclosed |
| US-4053509-A | ADAMANTANE-CARBOXAMIDES OR CYCLOPROPANE-CARBOXAMIDES, CNS DRUGS ON | SCHERING CORPORATION (US) | 1977-10-11 | — | — | US | disclosed |
| US-3944675-A | Substituted aryl and aralkyl amides in the treatment of parkinsonism | SCHERING CORPORATION (US) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551465-B2 | Pharmaceutical composition for treatment of hypertrophic cardiomyopathy and treatment method using same composition | ME2, TNNT2, TNNC1 | EPHX2 2183/4885KMT2A 2799/4885MAPT 2347/4885 |
| US-20250320198-A1 | SALT OF ENDOTHELIN A (ETA) RECEPTOR ANTAGONIST COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | EDNRA, EDNRB, ECE1 | EPHX2 1015/4885KMT2A 2760/4885MAPT 3831/4885 |
| US-20230190708-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF HYPERTROPHIC CARDIOMYOPATHY AND TREATMENT METHOD USING SAME COMPOSITION | ATP2A2, CPT1B, TNNT2 | EPHX2 1858/4885KMT2A 2425/4885MAPT 1632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.